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(popliteal 122 (29%), tibial 238 (56%), pedal 63 (15%)) were
analyzed.
258 (61%) patients received a single segment GSV, 118 (28%) an
AAV and 47 (11%) a prosthetic conduit. Postoperative outcomes
had no signiﬁcant differences among groups. Primary patency at 2
years for the GSV, AAV and prosthetic groups was 47%, 26% and
40% respectively. AAV demonstrated the poorest primary patency
rates, though non-statistically signiﬁcant compared to the pros-
thetic group (P ¼ .068). Primary assisted patency at 2 years for the
GSV, AAV and prosthetic groups was 70%, 52% and 45% respec-
tively. The primary-assisted patency of GSV was signiﬁcantly su-
perior to both AAV (P ¼ .008) and prosthetic grafts (P ¼ .002),
which did not differ signiﬁcantly from one another (P ¼ .479).
Secondary patency at 2 years for the GSV, AAV and prosthetic
groups was 75%, 57% and 46% respectively and again AAV and
prosthetic grafts did not differ signiﬁcantly from one another (P ¼
.212). In Cox regression analysis primary, primary assisted and
secondary patency were positively predicted by GSV (HR 1.65, P ¼
.001; HR 1.65, P ¼ .006; HR 1.72, P ¼ .006 respectively) when
compared to AAV, but there was no difference between AAV and
prosthetic grafts. Neither target artery (popliteal vs. tibial/pedal)
or runoff score, nor statins showed any predictive value. Limb
salvage at 2 years for the GSV, AAV and prosthetic groups was
87%, 77% and 74% respectively with no signiﬁcant differences
among groups.
Conclusion: When GSV is not available, alternative autologous vein
conduits do not offer a signiﬁcant patency advantage in midterm
follow up over prosthetic bypasses for below knee targets.The Receptor for Advanced Glycation End Products (RAGE) and
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Introduction: Objective: To investigate if RAGE and its ligands are
associated with outcome in patients with and without diabetes
undergoing infrainguinal bypass surgery.
Methods: A prospective observational study with at least 3 years
follow upwas conducted in 68 patients (57%male) with (n¼ 38) and
without (n ¼ 30) diabetes undergoing their ﬁrst elective infrain-
guinal vein bypass due to peripheral arterial occlusive disease.
Endosecretory RAGE (esRAGE), S100A12, advanced glycation end
products and carboxymethyl-lysine (CML) were determined in
plasma using ELISA. Inﬂuence of plasma levels on themain outcome
measure (amputation free survival) was evaluated using Cox pro-
portional hazard regression analysis. Plasma levels of esRAGE, CML
and S100A12 in healthy controls (n ¼ 30) without cardiovascular
disease matched for sex and age were compared to patients, using
ManneWhitney U test. S100A12, RAGE, AGE and CML in vein tissue
obtained at bypass surgery were determined using
immunohistochemistry.
Results: Forty-six patients survived with intact leg during a median
follow up of 702 days, (IQR 188 to 899). Seventeen died, and 6
were amputated. High plasma levels of S100A12 were associated
with reduced amputation free survival, (hazard ratio [HR] 2.99;
95% CI 1.24e7.24) when comparing levels above the 75th
percentile with levels below. The increased risk was essentially
unchanged adjusting for age, sex and diabetes (HR 2.58; 95% CI
1.05e6.35).Diabetic patients had higher mean S100A12 plasma levels,
11.75 ng/mL; 95% CI 8.12e15.38 compared to non diabetic pa-
tients 5.01; 3.62e6.41 (P ¼ .002), whereas levels of CML, esRAGE
and AGE were comparable. Mean plasma levels of CML and
S100A12 were higher in patients compared to controls, 1.25 mg/
mL; 95% CI 1.18e1.32 versus 0.89; 0.82e0.96 (P ¼ .001), and 8.73
ng/mL; 95% CI 6.52e10.95 versus 3.47; 2.95e3.99 (P < .001),
respectively. Diabetic patients did not differ from non diabetic
patients in the proportion of vein tissue area stained for AGE
(21%), RAGE (5%), CML (9%) and S100A12 (3%), and staining was
found in all veins with the same percentage in both diabetic and
non diabetic patients.
Conclusion: Plasma levels of S100A12 and CML are elevated in
peripheral arterial occlusive disease and markers of RAGE and its
ligands are found in vein tissue used for bypass. This may indicate a
role for S100A12, CML and RAGE in peripheral arterial disease
complications by activation of the RAGE system.Renal Outcomes Following Fenestrated and Branched
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Introduction: The purpose of this study was to analyze immediate
and long-term renal outcomes (renal function and renal events)
after fenestrated (FEVAR) and branched endovascular aortic
aneurysm repair (BEVAR).
Methods: All FEVAR and BEVAR performed between October 2004
and October 2012 were included in this study. Postoperative acute
renal failure (ARF) was deﬁned and classiﬁed according to the
RIFLE criteria. Renal volume (calculated with a 3D workstation) and
eGFR (estimated with the MDRD formula) were evaluated before
the procedure, before discharge, 12 months after and yearly
thereafter. Renal stent occlusion, dissection, fracture, stenosis,
kink, renal stent related type III endoleak and renal stent sec-
ondary intervention were all considered “renal composite events”
and analyzed. A time-to-event analysis was performed for renal
events and renal secondary interventions.
Results: During the study period, 225 patients were treated with
FEVAR and BEVAR. Renal target vessels (n ¼ 427) were perfused
by fenestrations (n ¼ 274) or branches (n ¼ 53). Median follow-up
was 2.4 years (2.2e2.6). FEVAR and BEVAR were associated with
similar mean renal artery diameter and renal artery angulations.
Preoperative renal stenosis rate was higher with BEVAR (p <
0.021). Technical success was achieved in 96.4% of patients.
Postoperative ARF was depicted in 64 patients (29%), requiring
transient hemodialysis in 12 patients (5.3%) and permanent he-
modialysis in one case (0.44%). An additional 4 patients (1.9%)
required hemodialysis during follow-up. Signiﬁcant decrease in
right renal volume (17.07 cm3; 95% conﬁdence interval (CI),
12.52e21.67), left renal volume (24.55 cm3; 95% CI, 19.14e29.97)
and eGFR (12.54 ml/min per 1.73 m2; 95% CI, 8.43e16.66) were
observed during follow-up (p < 0.000). The 30-day, 1-year and 5-
year freedom from renal composite event was 98.1% (95% CI,
97.2%e99%), 95% (95% CI, 93.5%e96.5%) and 87.5% (95% CI,
84.7%e90%). Freedom for renal composite events was signiﬁ-
cantly higher in FEVAR (p < 0.048) compared to BEVAR. The 30-
day, 1-year and 5-year freedom from renal occlusion was 99.5%
(95% CI, 99%e100%), 98.5% (95% CI, 97.6%e99.4%) and 93.8%
(95% CI, 91.7%e95.9%) after FEVAR and BEVAR (NS). Median time
